For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220926:nRSZ6876Aa&default-theme=true
RNS Number : 6876A Eco Animal Health Group PLC 26 September 2022
26 September 2022
ECO Animal Health Group plc ("the Company")
(AIM: EAH)
Result of Annual General Meeting
ECO Animal Health Group plc announces that at its Annual General Meeting held
earlier today ("AGM") all resolutions proposed to the meeting were duly
passed.
Proxy votes received in relation to each resolution were as follows:
Resolution For Against Withheld
% Discretionary % %
01 41,113,787 6,541,662 Nil
86.2178 30,535 0.0640 13.7182
02 47,645,198 251 10,000
99.9354 30,535 0.0640 0.0005
03 251 Nil
47,655,198 99.9354 30,535 0.0640 0.0005
04 47,632,825 22,624 Nil
99.8885 30,535 0.0640 0.0474
05 40,913,787 6,753,190 Nil
85.7983 19,007 0.0398 14.1618
06 47,644,711 10,487 251
99.9139 30,535 0.0640 0.0219
07 47,646,815 2,633 6,001
99.9304 30,535 0.0640 0.0055
47,642,165 12,283 1,001
08 99.9102 30,535 0.0640 0.0258
Contacts:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
IFC Advisory 020 3934 6630
Graham Herring
Zach Cohen
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Mark Taylor
George Tzimas
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Brough Ransom
Carlo Spingardi
Peel Hunt LLP (Joint Broker) 020 7418 8900
Dr Christopher Golden
James Steel
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGSESFIMEESESU